Supply Chain Intelligence

Atossa Therapeutics, Inc. Supply Chain

ATOS supply chain intelligence for Atossa Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

ATOS ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

8Suppliers
5Customers
2Debt Items
20Related Chains

Source-Backed Evidence Depth

Atossa Therapeutics, Inc. (ATOS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

16Total relationships
5Distinct source URLs
10High confidence
0.813Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Atossa Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
PRIMARY-COMMERCIAL-SUPPLIER PRIMARY-COMMERCIAL-SUPPLIER 92% In particular, our current business structure contemplates, at least in the foreseeable future, use of a primary commercial supplier for the (Z)-endoxifen drug substance.
PRIMARY-COMMERCIAL-SUPPLIER-FOR-THE-31-Z-ENDOXIF PRIMARY-COMMERCIAL-SUPPLIER-FOR-THE-31-Z-ENDOXIF 92% In particular, our current business structure contemplates, at least in the foreseeable future, use of a primary commercial supplier for the 31 (Z)-endoxifen drug substance.
PRIMARY-COMMERCIAL-SUPPLIER-FOR-THE-Z-ENDOXIFEN- PRIMARY-COMMERCIAL-SUPPLIER-FOR-THE-Z-ENDOXIFEN- 92% In particular, our current business structure contemplates, at least in the foreseeable future, use of a primary commercial supplier for the (Z)-endoxifen drug substance.
RODMAN-RENSHAW-LLC RODMAN-RENSHAW-LLC 92% Rodman & Renshaw LLC (the “Placement Agent”) acted as the exclusive placement agent for the Company in connection with the Offering.
INTAS-PHARMACEUTICALS-LTD INTAS-PHARMACEUTICALS-LTD 90% the Company entered into a Settlement Agreement with Intas Pharmaceuticals Ltd.
JINA-PHARMACEUTICALS-INC JINA-PHARMACEUTICALS-INC 90% the Company entered into a Settlement Agreement with Jina Pharmaceuticals, Inc.
THIRD-PARTY-INFORMATION-TECHNOLOGY-VENDOR THIRD-PARTY-INFORMATION-TECHNOLOGY-VENDOR 90% We also rely on a third-party information technology vendor to oversee our information technology systems, including our mechanisms, controls, technologies, systems, and other processes designed to h…
WKEY WISeKey International Holding AG 62% Reciprocal relationship from WKEY graph: -between-2022-and-2030 6 https://www.fortunebusinessinsights.com/north-america-electric-vehicle-charging-station-market-108624 7 https://iot-analytics.com/num…

Atossa Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
SNYNF Sanofi 72% pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses. Our operations are based primarily in Seattle, Washington. These operations could be su…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from ATOS graph: pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses. Our …
ATHENA-DIAGNOSTICS-INC ATHENA-DIAGNOSTICS-INC 62% pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses. Our operations are based primarily in Seattle, Washington. These operations could be su…
AUSTRALIA-ATOSSA-GENETICS-AUS-PTY-LTD AUSTRALIA-ATOSSA-GENETICS-AUS-PTY-LTD 62% pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses. Our operations are based primarily in Seattle, Washington. These operations could be su…
MYRIAD-THERAPEUTICS-INC MYRIAD-THERAPEUTICS-INC 62% pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses. Our operations are based primarily in Seattle, Washington. These operations could be su…

Atossa Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
ATOS-DEBT-7952 Warrants outstanding: 4318475 90% xbrl warrant detail from xbrl 2026-03-31.
ATOS-DEBT-7953 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.

Atossa Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Atossa Therapeutics, Inc..

Atossa Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
ATOS-OWNER-BARCLAYS-PLC BARCLAYS PLC 90% 13F overlay lists BARCLAYS PLC as top holder; 3 tracked holders.

Atossa Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
GRDX GridAI Technologies Corp. 100.00 2
ADAG Adagene Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
SVA Sinovac Biotech Ltd. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
CALC CalciMedica, Inc. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
BMRN BioMarin Pharmaceutical Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Atossa Therapeutics, Inc..

Unlock full ATOS data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
ATOS
Unlock ATOS Supply Chain Data
Verified relationships include:
PRIMARY-COMMERCIAL-SUPPLIERPRIMARY-COMMERCIAL-SUPPLIERSupplier92%
PRIMARY-COMMERCIAL-SUPPLIER-FOR-THE-31-Z-ENDOXIFPRIMARY-COMMERCIAL-SUPPLI…Supplier92%
SNYNFSanofiCustomer72%
SNYNFSanofiCustomer72%
+12 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →